Preventing Recurrent Urinary Tract Infections Using Non-Harmful E.coli Bladder Flushing A Placebo-Controlled Study at Odense University Hospital

What this Trial Is About

Urinary tract infection UTI is a common bacterial infection affecting millions worldwide, with recurrent cases leading to high antibiotic use and health costs. This trial investigates alternative treatments by studying the ability of a non-pathogenic E.coli strain ABU to prevent recurrent UTIs by outcompeting the harmful bacteria. The study is a placebo-controlled, double-blind clinical trial aimed at strengthening evidence for this approach. Participants will be randomly assigned to one of two groups one receiving bladder flushing with the non-pathogenic ABU bacterial strain as a preventive treatment, and the other receiving bladder flushing with a saline solution as a placebo. This study uses a quadruple-blind design to ensure unbiased results and focuses on evaluating the clinical effect of these interventions in preventing recurrent cystitis. During the 1-year follow-up, participants will undergo various assessments including monitoring the number of UTI events, time to first UTI after intervention, quality of life questionnaires, symptom scoring, and microbiological and laboratory tests. Safety aspects such as complications and hospitalizations will also be tracked. The study includes patients with different bladder conditions and requires regular clinical and microbiological evaluations throughout the trial period.

Bacterial Interference for Preventing Recurrent Urinary Tract Infection - New Ways of Treatment